300759 Pharmaron Beijing
- 19.99
- -0.17-0.84%
Pharmaron Beijing News
Contract research organizations are generally declining. Wuxi Apptec (02359) fell 9.74%. The uncertainty of the Biosecurity Law Bill weakened investor confidence.
Jinwu Finance News | The concept of contract research organizations is generally trending downward. Wuxi Apptec (02359) fell 9.74%, Frontage (01521) fell 5.36%, Tigermed (03347) fell 4.57%, Wuxi Bio (02269) fell 3.7%, and Pharmaron (03759) fell 3.13%. Citigroup has released a report stating that the U.S. House of Representatives has passed the Biosecurity Bill, but it is currently unknown whether the Senate will adopt the House version of the bill, or consider another version, or even incorporate the Biosecurity Bill into a larger comprehensive bill. Nevertheless, Citigroup believes that
HK stocks fluctuate | CRO concept stocks plummeted in early trading. The U.S. House of Representatives has passed the draft of the Biosecurity Law, and related companies have quickly issued clarification announcements.
CRO concept stocks tumbled in the morning session, as of the time of publication, wuxi apptec (02359) fell by 9.74%, closing at HK$32.45; frontage (01521) fell by 10.71%, closing at HK$0.5; pharmaron (03759) fell by 4.31%, closing at HK$8.87; tigermed (03347) fell by 3.66%, closing at HK$26.35.
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
gtja: The new signed orders for CXO in the first half of the year show a positive trend, and the API profitability is improving gradually by quarter.
In the first half of the year, CXO performance is under short-term pressure, with a positive trend in new signings; the API destocking is nearing completion, and profitability is improving quarter by quarter.
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.
Hong Kong stocks soar with the collective rise of CRO concept stocks, as the Federal Reserve is expected to cut interest rates and new industry orders are accelerating recovery.
CRO concept stocks rose collectively, as of the publication, Joinn Laboratories (06127) rose 2.96% to HKD 7.3; Wuxi AppTec (02359) rose 2.56% to HKD 34.05; Asymchem Laboratories (06821) rose 2.5% to HKD 40.95.
HK Stocks | Pharmaron (03759) up more than 5%, pure profit in the first half of the year increased by 41.6% year-on-year, new orders showed steady growth.
Pharmaron (03759) rose more than 5%, as of press time, it rose 5.05%, to HKD 8.73, with a turnover of HKD 20.9506 million.
Kanglong Chemical: 2024 Semi-Annual Report
Kanglong Chemical: 2024 Semi-Annual Report Summary
PHARMARON: INTERIM RESULTS ANNOUNCEMENTFOR THE SIX MONTHS ENDED JUNE 30, 2024
Express News | Pharmaron Says H1 Net Profit up 41.6% Y/Y
Hong Kong stocks are active | Early gains in CRO concept stocks, the Fed may start cutting interest rates in September, and overseas investment in innovative drugs has gradually shown an upward trend.
CRO concept stocks rose in early trading. As of the time of publication, Wuxi Bio (02269) rose by 4.68% to HK$10.74; Wuxi Apptec (02359) rose by 4.62% to HK$32.85; Tigermed (03347) rose by 3.17% to HK$29.3; Pharmaron (03759) rose by 2.48% to HK$8.28.
Hong Kong stock market anomaly | Asymchem Laboratories (06821) fell more than 4%, leading the CRO concept. The industry's performance is generally under pressure due to the decline in investment and financing in the pharmaceutical industry.
CRO concept stocks fell today. As of press time, Asymchem Laboratories (06821) fell 3.74%, at HKD 39.9; Tigermed (03347) fell 3.67%, at HKD 30.2; Pharmaron (03759) fell 3.06%, at HKD 8.55; Wuxi AppTec (02359) fell 2.88%, at HKD 32.05.
Sinolink: The results of the negotiations on drug prices in the United States have been announced, and the continuous procurement of medical devices domestically is ongoing.
Bullish on the development of the domestic medical devices industry in the second half of the year, with the industry's purchasing demand expected to accelerate recovery. At the same time, domestic leading companies in sub-sectors such as ultrasound and endoscopy, due to their strong competitiveness, are expected to further increase market share, with sales growth and profitability expected to return to an upward trend.
Pharmaron (03759) plans to acquire 80 million yuan of unsubscribed but yet-to-be paid AstraZeneca fund shares held by Jiangsu Yuyue Medical Equipment & Supply.
Pharmaron (03759) has announced to fully leverage its industry-leading position in medical and health fields as well as its globalized industry chain.
Jiangsu Yuyue Medical Equipment & Supply (002223.SZ) intends to transfer its shares of industrial investment fund to Pharmaron.
On August 16th, Gelunhui reported that Jiangsu Yuyue Medical Equipment & Supply Co., Ltd. (002223.SZ) announced that the company signed a "Transfer Agreement of Property Interests in Wuxi AstraZeneca CITIC Entrepreneurial Investment Partnership Enterprise (Limited Partnership)" with Pharmaron (Beijing) New Drug Technology Co., Ltd. (referred to as "Pharmaron"), CITIC Private Equity Funds Management Co., Ltd. (referred to as "CITIC Private Equity"), and AstraZeneca Business Consulting (Wuxi) Co., Ltd. (referred to as "AstraZeneca") on August 16, 2024. The company transferred its subscribed capital contribution to the partnership enterprise of RMB 80 million to Pharmaron at a price of RMB 0.
Pharmaron (03759.HK) held a board of directors meeting on August 27 to review and approve its mid-term performance.
Pharmaron (03759.HK) announced on August 14th that the board of directors meeting will be held on Tuesday, August 27th, 2024 to review and approve the interim performance of the company and its subsidiaries for the six months ended June 30th, 2024, which includes its release.
PHARMARON: NOTICE OF BOARD MEETING
Analysis
Price Target
No Data
